Clinical trials: Solid Cancer
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (1 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a…
- Trial name
- NCT05868629
- Testing
- Non-investigational
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasm Metastasis
A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
This study is a rolling arm study of pembrolizumab in combination with investigational agents in pediatric participants with relapsed or refractory classical Hodgkin lymphoma (cHL) solid tumors with microsatellite…
- Trial name
- NCT06395090
- Testing
- Pembrolizumab, Favezelimab, Favezelimab/Pembrolizumab
- Where
- 12 sites in United States, South Korea and 1 more
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Stage Solid Tumors
ATRi Transition Rollover Study
The main purpose of the study was to monitor the safety of participant receiving long-term treatment of Berzosertib as monotherapy.
- Trial name
- NCT03309150
- Testing
- Berzosertib
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia
Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children
The aim of this study was to investigate the occurrences of respiratory symptoms risk factors and abnormalities in lung function in young children (3-6 years old) with hemato-oncologic diseases at presentation (before treatment)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, Solid Tumors,, Hodgkin's Disease
- Trial name
- NCT00552825
- Where
- Israel
- Volunteers
- 35 people
- Sponsor
- Sheba Medical Center
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Advanced Solid Tumors
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
- Trial name
- NCT05533697
- Testing
- mRNA-4359, Pembrolizumab, Ipilimumab
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 361 people
- Sponsor
- ModernaTX, Inc.
Colorectal Cancer, Locally Advanced
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain.
- Conditions
- Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT00819169
- Testing
- AMG 479, AMG 655
- Volunteers
- 89 people
- Sponsor
- NantCell, Inc.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
Modern frontline therapy for patients with hematologic malignancies is based on intensive administration of multiple drugs. In patients with relapsed disease, response to the same drugs is generally poor, and dosages cannot be…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell, Juvenile Myelomonocytic Leukemia Lymphoblastic, T-cell Lymphoblastic Lymphoma
- Trial name
- NCT00640796
- Testing
- Haploidentical donor derived natural killer cell infusion, Chemotherapy, CliniMACS
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- St. Jude Children's Research Hospital
Solid Tumours, CNS Tumours
A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR
This is an open-label, sequential dose exploration study of single agent EEDVSMit administered by intravenous (IV) infusion twice weekly, followed by weekly maintenance dosing, in children with recurrent/refractory solid or CNS…
- Trial name
- ECREST (NCT02687386)
- Testing
- Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)
- Where
- 2 sites in Australia
- Volunteers
- 9 people
- Sponsor
- Dr David Ziegler
Pediatric Solid Tumors
Molecular Analysis Of Solid Tumors
This study will prospectively characterize the molecular, cellular and genetic properties of primary and metastatic neuroblastoma, osteosarcoma, retinoblastoma, Ewing sarcoma family of tumors, soft tissue sarcomas, adrenocortical…
- Trial name
- MAST (NCT01050296)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- St. Jude Children's Research Hospital
Wilms Tumor, Rhabdoid Tumor
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher…
- Conditions
- Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST
- Trial name
- NCT05985161
- Testing
- Selinexor
- Where
- 16 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Unspecified Childhood Solid Tumor, Protocol Specific
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
This phase I trial studies the side effects and the best dose of temsirolimus when given together with irinotecan hydrochloride and temozolomide in treating younger patients with recurrent or refractory solid tumors.
- Trial name
- NCT01141244
- Testing
- temsirolimus, temozolomide, irinotecan hydrochloride
- Where
- 25 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Recurrent, Brain Tumor, Pediatric
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
The PIRATE study tests the experimental drug RRx-001 in combination with 2 chemotherapy drugs that are commonly used in patients with cancer. RRx-001 has been used alone and with other anti-cancer medicines in adults.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Pediatric, Central Nervous System Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- PIRATE (NCT04525014)
- Testing
- RRx-001, Temozolomide, Irinotecan
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- EpicentRx, Inc.
Childhood Solid Tumors
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
The drug, talazoparib, seems to work against cancer in test tubes and animals by preventing DNA repair in damaged cells leading to their death.
- Trial name
- NCT02392793
- Testing
- Talazoparib, Irinotecan, Temozolomide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- St. Jude Children's Research Hospital
Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does…
- Conditions
- Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27-Altered
- Trial name
- NCT04870944
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy
- Where
- 35 sites in United States, Australia
- Volunteers
- 63 people
- Sponsor
- Children's Oncology Group
Hematologic Malignancy, Solid Tumor
Voraxaze for Delayed Methotrexate Clearance
Primary Objectives: 1. To evaluate the efficacy of Glucarpidase (Voraxaze) in increasing the rate of methotrexate (MTX) clearance following high dose MTX treatment in patients with a delayed MTX clearance. 2.
- Trial name
- NCT00424645
- Testing
- Voraxaze (Glucarpidase)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Adult, Solid Tumor, Childhood
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
This is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs.
- Conditions
- Solid Tumor, Adult, Solid Tumor, Childhood, Hematologic Cancer
- Trial name
- PIONEER (NCT05481502)
- Testing
- Tumor biopsy, Blood sample, Bone marrow sample
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Pediatric Solid Tumor, Unspecified, Protocol Specific
Liquid Biopsies in Pediatric Solid Tumors
This study is being done to determine if traces of tumor can be found in the blood before, during, and after patients stop treatment.
- Trial name
- NCT05068583
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Los Angeles
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
This phase I trial is studying the side effects and best dose of dasatinib in treating young patients with recurrent or refractory solid tumors or Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00316953
- Testing
- dasatinib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00003766
- Testing
- O6-benzylguanine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Chicago